MRK Merck & Co Inc
Price (delayed)
$87.12
Market cap
$220.07B
P/E Ratio
12.89
Dividend/share
$3.16
EPS
$6.76
Enterprise value
$243.94B
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the
Highlights
The P/E is 82% lower than the 5-year quarterly average of 73.2 and 75% lower than the last 4 quarters average of 51.6
The net income is up by 41% since the previous quarter
MRK's quick ratio is up by 24% year-on-year but it is down by 4.5% since the previous quarter
MRK's debt is up by 6% year-on-year but it is down by 2.7% since the previous quarter
Key stats
What are the main financial stats of MRK
Market
Valuations
Earnings
Shares outstanding
2.53B
Market cap
$220.07B
Enterprise value
$243.94B
Price to earnings (P/E)
12.89
Price to book (P/B)
4.76
Price to sales (P/S)
3.44
EV/EBIT
11.51
EV/EBITDA
9.5
EV/Sales
3.8
Revenue
$64.17B
Gross profit
$48.98B
Operating income
$19.91B
Net income
$17.12B
EBIT
$21.19B
EBITDA
$25.69B
Free cash flow
$18.1B
Per share
Balance sheet
Liquidity
EPS
$6.76
EPS diluted
$6.74
Free cash flow per share
$7.15
Book value per share
$18.31
Revenue per share
$25.34
TBVPS
$31.23
Total assets
$117.11B
Total liabilities
$70.73B
Debt
$37.11B
Equity
$46.31B
Working capital
$10.36B
Debt to equity
0.8
Current ratio
1.36
Quick ratio
0.84
Net debt/EBITDA
0.93
Margins
Efficiency
Dividend
EBITDA margin
40%
Gross margin
76.3%
Net margin
26.7%
Operating margin
31%
Return on assets
15.1%
Return on equity
39.2%
Return on invested capital
28.9%
Return on capital employed
23.9%
Return on sales
33%
Dividend yield
3.63%
DPS
$3.16
Payout ratio
46.7%
MRK stock price
How has the Merck stock price performed over time
Intraday
-2.94%
1 week
-0.85%
1 month
-5.56%
1 year
-33.49%
YTD
-12.42%
QTD
-2.94%
Financial performance
How have Merck's revenue and profit performed over time
Revenue
$64.17B
Gross profit
$48.98B
Operating income
$19.91B
Net income
$17.12B
Gross margin
76.3%
Net margin
26.7%
Merck's operating income has increased by 46% from the previous quarter
Merck's operating margin has increased by 44% QoQ
The net income is up by 41% since the previous quarter
MRK's net margin is up by 39% since the previous quarter
Growth
What is Merck's growth rate over time
Valuation
What is Merck stock price valuation
P/E
12.89
P/B
4.76
P/S
3.44
EV/EBIT
11.51
EV/EBITDA
9.5
EV/Sales
3.8
The P/E is 82% lower than the 5-year quarterly average of 73.2 and 75% lower than the last 4 quarters average of 51.6
The EPS has grown by 41% from the previous quarter
The price to book (P/B) is 30% lower than the last 4 quarters average of 6.8 and 26% lower than the 5-year quarterly average of 6.4
Merck's equity has increased by 23% YoY and by 4.1% from the previous quarter
MRK's P/S is 27% below its last 4 quarters average of 4.7 and 25% below its 5-year quarterly average of 4.6
The revenue has grown by 7% YoY
Efficiency
How efficient is Merck business performance
The ROS has grown by 39% from the previous quarter
The ROIC rose by 39% QoQ
The company's return on assets rose by 37% QoQ
Merck's ROE has increased by 34% from the previous quarter
Dividends
What is MRK's dividend history
DPS
$3.16
Dividend yield
3.63%
Payout ratio
46.7%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Merck financials performed over time
The total assets is 66% more than the total liabilities
MRK's quick ratio is up by 24% year-on-year but it is down by 4.5% since the previous quarter
The total assets has grown by 10% YoY
MRK's debt is 20% smaller than its equity
Merck's equity has increased by 23% YoY and by 4.1% from the previous quarter
The debt to equity has contracted by 14% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.